Login / Signup

Re: Thomas Powles, Zoe June Assaf, Viraj Degaonkar, et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. Eur Urol 2024;85:114-22.

Viria BecciaGiada PinterpeRoberto Iacovelli
Published in: European urology (2024)
Keyphrases
  • circulating tumor
  • cell free
  • circulating tumor cells
  • early stage
  • study protocol
  • phase iii
  • skeletal muscle
  • clinical trial
  • phase ii
  • free survival
  • open label